You are here

Innovative Chemogenomic Tools to Improve Outcome in Acute Myeloid Leukemia

Status: 
Active
Competition: 
2012 Large-Scale Applied Research Project Competition – Genomics and Personalized Health
Sector: 
Health
Genome Centre(s):
Génome Québec
Project Leader(s):
Guy Sauvageau (Institute for Research in Immunology and Cancer), Josée Hébert (Hôpital Maisonneuve Rosemont)
Fiscal Year Project Launched: 
2012-2013
Project Description: 

Acute myeloid leukemia is a particularly lethal type of cancer among  young people, with most dying within two years of being diagnosed. At the moment,  analyzing cancer cell chromosomes is the best way to determine the prognosis for  patients. Unfortunately, about 45 per cent of those tested show no anomalies, leaving doctors with little information to go on. Recent developments in DNA sequencing, however, allow for a more complete analysis of these tumors.

Drs. Guy Sauvageau, Josée Hébert and team will use personalized DNA from patients to determine how they should be treated, based on the specific genetic makeup of their tumors. This will lead to better diagnosis and improved outcomes for patients. They are also developing new models for tracking cancer cells that are left behind after a patient is treated. These cancer stem cells can multiply over time and lead to a relapse. This research could lead to new ways of preventing such relapses by providing new insights into the biology of this disease.